Researchers developed pH-responsive chitosan nanoparticles encapsulating NMN to overcome bioavailability and rapid clearance limitations in acute kidney injury treatment. The delivery system activates SIRT1 signaling, suppresses NF-κB inflammation, reduces oxidative stress, and promotes tubular repair in kidney injury models. This represents a significant advance in NMN formulation technology that directly addresses a core challenge in oral peptide/supplement delivery: achieving sustained therapeutic effect with reduced dosing frequency.
For your business
NMN nanoparticle delivery enhanced renal bioavailability in preclinical models, suggesting formulation may matter for clinical dosing strategy.